1[1]Sever PS,Dahlof B,Poulter NR,et al. Prevention of coronary and stroke events with atorvastatin in hypertension patients who have average or lower-than-average cholesterol concentration,in the Angio-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm(ASCOT-ALL): a multicen-tre randomized controlled trial[J]. Lancet,2003;361:1149～1158 被引量：1
2[2]Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes:a randomised placebo-controlled trial[J]. Lancet,2003;363:2005～2016 被引量：1
3[3]The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcome in high-risk hypertension patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:the Antihypertension and Lipid-Lowering Treatment To Prevent Heart Attack Trial(ALLHAT)[J].JAMA,2002;288:2981～2997 被引量：1
4[4]Frohlich E D.Treating hypertension-what are we to believe? [J].N Engl J Med,2003;348:639～641 被引量：1
5[5]Wing L M H,Reid C M,Ryan P,et al,A comparison of outcome with angiotensin-converting enzyme inhibitors and diuretic for hypertensionin the elderly[J].N Engl J Med,2003;348:583～592 被引量：1
6[6]Chobanian AV,Bakris GL,Black HR,et al.The seventh report of the joint national committee on prevention,detection,evaluation,and treatment of high blood pressure.The JNC 7 Report[J].JAMA,2003;289:2560～2572 被引量：1
7[7]Guidelines Committee.2003 European society of hypertension-European society of Cardiology guidelines for the management of arterial hypertension[J].J Hypertens,2003;21:1011～1053 被引量：1
8[8]Fox KM,Bertrand M,Ferrari R,et al. Efficacy of perindoprl in reduction cardiovascular events among with stale coronary artery disease:randomized,double-blind, placebo-controlled, multicentre trial-- The European on reduction of cardiac events with perindoprl in stale coronary artery disease investigators(EUROPA)[J]. Lancet,2003;362:782～788 被引量：1
9[9]Pfeffer MA,McMurray JJ,Velazquez EJ,et al. Valsartan captopril,or both in myocardial infarction complicated by heart failure,left ventricular dysfunction,or both. Valsartan in acute myocardial infarction trial (VALIANT)[J]. N Engl J Med,2003;349(20):1893～1906 被引量：1
10[10]Poole-Wilson PA,Swedbery K,Cleland JGF,et al. for the COMET investigators,comparison of Carvedilol and Metoporplal on clinical outcome in patients with chronic heart failure in the Carvedilol and Metoporplal European Trial(COMET): randomized controlled trial [J]. Lancet,2003,362:782～788 被引量：1
5Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndrome:The GRACE study [ J]. Ann Intern Med, 2004, 140( 11 ) :857 - 866. 被引量：1
7Maron DJ,Fazio S,Linton MF.Current perspectives on statins [J].Circulation,2000,101(2):207～213 被引量：1
8Bustos C,Hernandez-Presa MA,Ortego M,et al.HMG-GoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis[J].J Am Coll Cardiol,1998,32(7):2057～2064 被引量：1
10Banach M, Markuszewski L, Zaslonka J, et al. The role of inflam- mation in the pathogenes is of atherosclemsis [ J ]. Przegl Epidemi- ol,2004,58(4) :663-670. 被引量：1
